Suppr超能文献

既往免疫抑制治疗是 Whipple 病免疫重建炎症综合征的一个危险因素。

Previous immunosuppressive therapy is a risk factor for immune reconstitution inflammatory syndrome in Whipple's disease.

机构信息

Coeliac Centre/First Dept of Internal Medicine, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Italy.

出版信息

Dig Liver Dis. 2012 Oct;44(10):880-2. doi: 10.1016/j.dld.2012.05.008. Epub 2012 Jun 15.

Abstract

INTRODUCTION

Whipple's disease is a rare chronic infection caused by Tropheryma whipplei. Although most patients respond to antibiotics, in some of them the start of the treatment is followed by recurrence of inflammation. Since polymerase chain reaction is negative for Tropheryma whipplei, this reinflammation cannot be a relapse of Whipple's disease itself. Very recently, it has been recognised as a complication of Whipple's disease and defined immune reconstitution inflammatory syndrome (IRIS). Our aim is to study the prevalence and the clinical features of IRIS in Italian patients with Whipple's disease.

METHODS

Evidence of IRIS was retrospectively revaluated in the clinical notes of 22 patients with Whipple's disease. Patients with no evidence of IRIS served as controls for the clinical findings.

RESULTS

Recurrence of arthralgia and/or fever allowed a diagnosis of IRIS in 5/22 patients. One patient died. Previous immunosuppressive therapy was found in all patients with IRIS but only in 7/17 controls (Fisher test, p=0.039). Age at diagnosis and diagnostic delay were higher in patients with IRIS compared to controls. However, statistical significance was not reached.

CONCLUSIONS

IRIS is a frequent complication of Whipple's disease and it can be fatal. The risk of IRIS is greatly increased in patients previously treated with immunosuppressive therapy.

摘要

简介

惠普尔病是一种由特罗尔氏体引起的罕见慢性感染。尽管大多数患者对抗生素治疗有反应,但在一些患者中,治疗开始后会出现炎症复发。由于特罗尔氏体聚合酶链反应呈阴性,这种再炎症不能是惠普尔病本身的复发。最近,它被认为是惠普尔病的一种并发症,并被定义为免疫重建炎症综合征(IRIS)。我们的目的是研究意大利惠普尔病患者中 IRIS 的患病率和临床特征。

方法

回顾性重新评估 22 例惠普尔病患者的临床记录中 IRIS 的证据。没有 IRIS 证据的患者作为临床发现的对照。

结果

5/22 例患者出现关节痛和/或发热复发,诊断为 IRIS。1 例患者死亡。所有 IRIS 患者均有既往免疫抑制治疗,但仅在 17 例对照中有 7 例(Fisher 检验,p=0.039)。与对照组相比,IRIS 患者的诊断年龄和诊断延迟较高。然而,未达到统计学意义。

结论

IRIS 是惠普尔病的常见并发症,可致命。先前接受过免疫抑制治疗的患者发生 IRIS 的风险大大增加。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验